| 1 |
NCT03114254 |
Completed |
A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis |
|
|
Interventional
|
Phase 2 |
- University Hospitals Bristol NHS Foundation Trust
- Sanofi
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete response
- Partial response
- Progression free survival
- (and 3 more...)
|
17 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03114254 |
ON/2012/4233
2014-002336-14
CabazL05881 |
JAVA-P |
December 5, 2014 |
November 16, 2016 |
November 16, 2016 |
April 14, 2017 |
April 14, 2017 |
|
- Bristol Haematology and Oncology Centre, Horfield Road
Bristol, United Kingdom - Universitty College Hospitals NHS Trust
London, United Kingdom
|
|
| 2 |
NCT02057913 |
Active, not recruiting |
A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP) |
- Locally-advanced or Metastatic Penile Neoplasms
|
|
Interventional
|
Phase 2 |
- Institute of Cancer Research, United Kingdom
- St George's Healthcare NHS Trust
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Benefit
- Objective Response Rate
- Toxicity
- (and 3 more...)
|
22 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02057913 |
ICR-CTSU/2012/10036
CRUK/12/021
2012-002592-34
13/LO/0822
CCR3858 |
VinCaP |
March 2014 |
September 2018 |
September 2018 |
February 7, 2014 |
May 23, 2017 |
|
- Velindre NHS Trust
Whitchurch, Cardiff, United Kingdom - Royal Cornwall Hospitals NHS Trust
Truro, Cornwall, United Kingdom - University College London Hospitals NHS Foundation Trust
London, Greater London, United Kingdom - (and 6 more...)
|
|
| 3 |
NCT01728233 |
Recruiting |
Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis |
- Penile Neoplasms
- Carcinoma, Squamous Cell
|
|
Interventional
|
Phase 2 |
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Pfizer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary outcome measure will be the assessment of response-rate (RR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- To assess the safety and tolerability of the study drug. Incidence, nature and severity of treatment-related adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
- Pathologic complete response (pCR) rate for patients undergoing surgery in the treatment time course.
- (and 3 more...)
|
37 |
Male |
18 Years to 75 Years (Adult, Older Adult) |
NCT01728233 |
INT110/12 |
HER-Uro01 |
June 15, 2013 |
October 15, 2017 |
February 15, 2018 |
November 19, 2012 |
March 9, 2017 |
|
- Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
|
|
| 4 |
NCT00066391 |
Completed |
Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer |
|
- Drug: cisplatin
- Drug: irinotecan hydrochloride
- Procedure: neoadjuvant therapy
|
Interventional
|
Phase 2 |
- European Organisation for Research and Treatment of Cancer - EORTC
|
Other |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate measured by RECIST at 8 weeks after completion of study treatment
- Duration of response as measured by Kaplan-Meier every 8 weeks until progression, and then every 3 months thereafter
- Toxicity as measured by NCI-CTC v2.0 every 8 weeks until progression
|
|
Male |
up to 75 Years (Child, Adult, Older Adult) |
NCT00066391 |
EORTC-30992 |
|
June 2003 |
January 2006 |
|
August 7, 2003 |
September 24, 2012 |
|
- U.Z. Gasthuisberg
Leuven, Belgium - Institut Gustave Roussy
Villejuif, France - National Institute of Oncology
Budapest, Hungary - (and 5 more...)
|
|
| 5 |
NCT00058448 |
Terminated |
S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) |
|
|
Interventional
|
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks during treatment
- Safety as measured by Common Terminology Criteria for Adverse Events (CTC) Version 3.0 every 4 weeks
|
1 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00058448 |
CDR0000297621
S0224
U10CA032102 |
|
October 2004 |
November 2005 |
November 2005 |
April 9, 2003 |
April 17, 2013 |
|
- St. Anthony Central Hospital
Denver, Colorado, United States - University of Colorado Cancer Center at University of Colorado Health Sciences Center
Denver, Colorado, United States - Veterans Affairs Medical Center - Denver
Denver, Colorado, United States - (and 46 more...)
|
|
| 6 |
NCT03418480 |
Recruiting |
HPV Anti-CD40 RNA Vaccine |
- Carcinoma, Squamous Cell
- Head and Neck Neoplasm
- Cervical Neoplasm
- Penile Neoplasms Malignant
|
|
Interventional
|
Phase 1
Phase 2 |
- University of Southampton
- Biontech AG
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity (DLT) according to CTCAE version 4.03 (Arm 1A)
|
44 |
All |
18 Years and older (Adult, Older Adult) |
NCT03418480 |
RHMCAN0983
2014-002061-30
ISRCTN51789191 |
HARE-40 |
April 11, 2017 |
September 2019 |
December 2020 |
February 1, 2018 |
May 9, 2018 |
|
- Univeristy Hospitals Southampton NHS Foundation Trust
Southampton, Hampshire, United Kingdom
|
|
| 7 |
NCT03391479 |
Not yet recruiting |
A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy |
- Penile Cancer
- Advanced Cancer
- Metastatic Cancer
|
- Drug: Avelumab
- Other: Best Supportive Care
|
Interventional
|
Phase 2 |
- University Health Network, Toronto
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate
- Progression-free Survival Rate
- Overall Survival Rate
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT03391479 |
WI222910 |
|
February 1, 2018 |
February 1, 2021 |
February 2, 2022 |
January 5, 2018 |
January 9, 2018 |
|
- Princess Margaret Cancer Centre
Toronto, Ontario, Canada
|
|
| 8 |
NCT02104063 |
Unknown † |
Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET] |
- Squamous Cell Carcinoma of the Penis
|
|
Observational
|
|
- Queen Mary University of London
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Evaluating the clinical validity (sensitivity, specificity, negative and positive predictive values) of whole-body MRI-PET to detect or exclude micrometastatic disease in inguinal lymph nodes.
|
107 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02104063 |
008956QM |
MRI-PET |
October 2013 |
March 2018 |
March 2018 |
April 4, 2014 |
October 2, 2017 |
|
- University College London Hospitals
London, United Kingdom
|
|
| 9 |
NCT00955929 |
Active, not recruiting |
Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy |
- Penile Cancer
- Erectile Dysfunction
- Radical Prostatectomy
|
- Drug: Placebo QHS and sildenafil and questionnaires
- Drug: Sildenafil and questionnaire
- Drug: Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
|
Interventional
|
Not Applicable |
- Memorial Sloan Kettering Cancer Center
- Pfizer
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Difference in the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) between the 3 groups at 24 months.
- The time to return of spontaneous functional erections.
- The time for patients to respond to oral erectogenic therapy.
- The proportion of patients who have normalization of their erectile function (normalization of the EF domain of the IIEF).
|
100 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00955929 |
09-005 |
|
August 2009 |
August 2018 |
August 2018 |
August 10, 2009 |
September 6, 2017 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
|
| 10 |
NCT03012581 |
Recruiting |
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types |
- Carcinoma, Renal Cell
- Head and Neck Neoplasm
- Skin Neoplasms
- (and 2 more...)
|
|
Interventional
|
Phase 2 |
- UNICANCER
- National Cancer Institute, France
- Ligue contre le cancer, France
- Bristol-Myers Squibb
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate
- Progression-free survival
- Overall survival
- (and 7 more...)
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT03012581 |
UC0105/1611
2016-002257-37 |
AcSé |
June 16, 2017 |
January 2023 |
December 2023 |
January 6, 2017 |
May 21, 2018 |
|
- Gustave Roussy Cancer Campus
Villejuif, France
|
|
| 11 |
NCT03333616 |
Recruiting |
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors |
- Genitourinary Cancer
- Adrenocortical Carcinoma
- Non-urothelial Bladder
- (and 4 more...)
|
- Drug: Ipilimumab
- Drug: Nivolumab
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Bristol-Myers Squibb
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate
- Objective Response Rate for all rare GU tumor types
- Duration of Response
- (and 4 more...)
|
57 |
All |
18 Years and older (Adult, Older Adult) |
NCT03333616 |
17-423 |
|
December 28, 2017 |
May 31, 2021 |
May 31, 2025 |
November 7, 2017 |
February 14, 2018 |
|
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
| 12 |
NCT02817958 |
Recruiting |
Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis (AFU-GETUG 25) |
- Penile Cancer
- Squamous Carcinoma
|
|
Interventional
|
Phase 2 |
- UNICANCER
- National Cancer Institute, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- survival without locoregional lymph node recurrence
- Complete response rate for patients in neoadjuvant chemotherapy
- Survival without locoregional lymph node recurrence
- (and 5 more...)
|
37 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02817958 |
UC-0160/1406
AFU-GETUG 25 |
MEGACEP |
April 2016 |
September 2021 |
September 2022 |
June 29, 2016 |
November 6, 2017 |
|
- ICO-Paul Papin
Angers, France - Chr Besancon
Besançon, France - Hôpital SAINT ANDRE
Bordeaux, France - (and 14 more...)
|
|
| 13 |
NCT02014831 |
Withdrawn |
Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) |
- Squamous Cell Carcinoma of the Penis
|
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluation of the antitumor activity of Cetuximab treatment in terms of Objective Response Rate (ORR) at the end of treatment
- Evaluation of the Safety Profile of Cetuximab treatment
- Evaluation of the antitumor activity of Cetuximab treatment in terms of Overall Survival (OS) at the end of the study
- (and 2 more...)
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT02014831 |
PENILANE |
PENILANE |
February 2016 |
February 2016 |
February 2016 |
December 18, 2013 |
February 25, 2016 |
|
- CHRU Strasbourg
Strasbourg, Bas Rhin, France - Institut Paoli Calmettes
Marseille, Bouches du Rhône, France - Institut Bergonié
Bordeaux, Gironde, France - (and 4 more...)
|
|
| 14 |
NCT00512096 |
Completed
Has Results |
Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis |
|
- Drug: Ifosfamide
- Drug: Paclitaxel (Taxol)
- Drug: Cisplatin
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Pathologic Complete Remission (pCR)
|
30 |
Male |
14 Years and older (Child, Adult, Older Adult) |
NCT00512096 |
ID99-194 |
|
August 1999 |
August 2010 |
August 2010 |
August 7, 2007 |
August 1, 2012 |
December 8, 2010 |
- U.T.M.D. Anderson Cancer Center
Houston, Texas, United States
|
|
| 15 |
NCT02280811 |
Completed
Has Results |
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers |
- Vaginal Cancer
- Cervical Cancer
- Anal Cancer
- (and 2 more...)
|
- Drug: Fludarabine
- Drug: Cyclophosphamide
- Biological: E6 TCR
- Drug: Aldesleukin
|
Interventional
|
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD)
- Objective Tumor Response Rate (Complete or Partial Response)
- Duration of Response
- (and 4 more...)
|
12 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02280811 |
150005
15-C-0005 |
|
October 14, 2014 |
June 28, 2016 |
June 28, 2016 |
November 3, 2014 |
September 6, 2017 |
August 2, 2017 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 16 |
NCT01585428 |
Completed
Has Results |
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers |
- Cervical Cancer
- Oropharyngeal Cancer
- Vaginal Cancer
- (and 2 more...)
|
- Drug: Fludarabine
- Drug: Cyclophosphamide
- Biological: Young TIL
- Drug: Aldesleukin
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With an Objective Clinical Response
- Number of Patients With Serious and Non-serious Adverse Events
|
29 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01585428 |
120116
12-C-0116 |
|
April 13, 2012 |
April 9, 2016 |
August 1, 2016 |
April 25, 2012 |
March 7, 2018 |
March 23, 2017 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 17 |
NCT01209325 |
Completed |
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males |
- Anal Cancer
- Nonneoplastic Condition
- Penile Cancer
- Precancerous Condition
|
- Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 2 |
- AIDS Malignancy Consortium
- National Cancer Institute (NCI)
- The EMMES Corporation
- (and 3 more...)
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Any incident of AIN or anal/perianal condyloma associated with HPV 16, 18, 6, or 11 DNA
- Diagnosis of HGAIN related to vaccine HPV types at any time during the study
- Any persistent anogenital infection with HPV 16, 18, 6, or 11 DNA
- (and 8 more...)
|
149 |
Male |
13 Years to 26 Years (Child, Adult) |
NCT01209325 |
AMC-072
U01CA121947
CDR0000685816 |
|
June 28, 2011 |
December 12, 2017 |
December 12, 2017 |
September 27, 2010 |
May 8, 2018 |
|
- Moores UCSD Cancer Center
La Jolla, California, United States - UCLA Clinical AIDS Research and Education (CARE) Center
Los Angeles, California, United States - Childrens Hospital Los Angeles
Los Angeles, California, United States - (and 15 more...)
|
|
| 18 |
NCT03427411 |
Recruiting |
M7824 in Subjects With HPV Associated Malignancies |
- Human Papilloma Virus
- Cervical Cancer
- Oropharyngeal Cancer
- (and 2 more...)
|
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (ORR)
- duration of response
- overall survival (OS)
- (and 3 more...)
|
90 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT03427411 |
180056
18-C-0056 |
|
February 27, 2018 |
December 31, 2020 |
December 31, 2020 |
February 9, 2018 |
May 9, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 19 |
NCT00019110 |
Completed |
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer |
- Anal Cancer
- Cervical Cancer
- Esophageal Cancer
- (and 3 more...)
|
- Biological: human papillomavirus 16 E7 peptide
- Biological: synthetic human papillomavirus 16 E6 peptide
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Primary Purpose: Treatment
|
|
|
Female |
18 Years and older (Adult, Older Adult) |
NCT00019110 |
CDR0000064330
NCI-95-C-0154
NCI-T94-0134N |
|
November 1995 |
|
|
January 27, 2003 |
April 29, 2015 |
|
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, United States - Center for Cancer Research
Bethesda, Maryland, United States - Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States - (and 3 more...)
|
|
| 20 |
NCT02994758 |
Recruiting |
Development of Diagnostics and Treatment of Urological Cancers |
- Prostate Carcinoma
- Kidney Cancer
- Urothelial Carcinoma
- (and 2 more...)
|
- Other: Personalised treatment
|
Interventional
|
Not Applicable |
- Helsinki University Central Hospital
- Karolinska Institutet
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Successful clinical translation
- Successful pre-clinical translation
- Translation of preclinical data into clinically useful data.
- Number of representative cell models developed from clinical samples.
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT02994758 |
None yet |
DEDUCER |
November 27, 2017 |
December 2020 |
December 2020 |
December 16, 2016 |
December 14, 2017 |
|
- Helsinki University Hospital
Helsinki, Uusimaa, Finland
|
|
| 21 |
NCT03346915 |
Not yet recruiting |
Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention |
- Human Papilloma Virus
- Cervical Cancer
- Human Papillomavirus Infection
- (and 5 more...)
|
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- HPV vaccine series start and completion
- HPV and Cervical Cancer awareness and knowledge
- Provider-patient communication about HPV vaccine and cervical cancer
- Wheel of Wellness (WoW) feasibility
|
30 |
All |
9 Years to 65 Years (Child, Adult, Older Adult) |
NCT03346915 |
H-36669 |
|
June 2018 |
December 2018 |
February 2019 |
November 20, 2017 |
May 8, 2018 |
|
|
|
| 22 |
NCT02496208 |
Recruiting |
Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors |
- Clear Cell Renal Cell Carcinoma
- Metastatic Malignant Neoplasm in the Bone
- Metastatic Penile Carcinoma
- (and 22 more...)
|
- Drug: Cabozantinib S-malate
- Biological: Ipilimumab
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recommended phase II dose defined as the highest dose for which no more than 1/6 patients experience a dose limiting toxicity evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I)
- Incidence of adverse events evaluated according National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I)
- Clinical response rate assessed by Response Evaluation Criteria in Solid Tumors 1.1 and Immune-Related Response Criteria
- (and 2 more...)
|
135 |
All |
18 Years and older (Adult, Older Adult) |
NCT02496208 |
NCI-2014-02379
P141706
150160
9681
UM1CA186712
UM1CA186716
UM1CA186717
ZIABC011078 |
|
July 9, 2015 |
September 30, 2019 |
|
July 14, 2015 |
April 3, 2018 |
|
- City of Hope Comprehensive Cancer Center
Duarte, California, United States - Los Angeles County-USC Medical Center
Los Angeles, California, United States - USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States - (and 5 more...)
|
|
| 23 |
NCT02012699 |
Recruiting |
Integrated Cancer Repository for Cancer Research |
- Pancreatic Cancer
- Thyroid Cancer
- Lung Cancer
- (and 44 more...)
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Development and implementation of a web-based Cancer Collaborative Registry at the University of Nebraska Medical Center (UNMC)/Nebraska Medical Center (NMC)
- Procurement and banking of excess biological material for future analysis
|
9999 |
All |
19 Years to 110 Years (Adult, Older Adult) |
NCT02012699 |
UNMC 253-13 |
iCaRe2 |
November 2013 |
December 2099 |
December 2099 |
December 16, 2013 |
May 9, 2017 |
|
- University of Alabama Birmingham
Birmingham, Alabama, United States - Penrose Cancer Center
Colorado Springs, Colorado, United States - Halifax Health Medical Center d/b/a Halifax Health
Daytona Beach, Florida, United States - (and 67 more...)
|
|
| 24 |
NCT01236053 |
Completed
Has Results |
Cancer in Patients With Gabapentin (GPRD) |
- Pain, Neuropathic
- Epilepsy
- Renal Pelvis Cancer
- (and 13 more...)
|
- Drug: Gabapentin prescriptions
|
Observational
|
|
|
Industry |
- Observational Model: Case-Control
- Time Perspective: Retrospective
|
- Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
- Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
- Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
- (and 52 more...)
|
2323608 |
All |
Child, Adult, Older Adult |
NCT01236053 |
114790
WEUSRTP4931 |
|
June 2010 |
September 2010 |
September 2010 |
November 8, 2010 |
July 6, 2017 |
August 4, 2011 |
|
|
| 25 |
NCT00002506 |
Completed |
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer |
- Cervical Cancer
- Esophageal Cancer
- Head and Neck Cancer
- (and 3 more...)
|
- Biological: recombinant interferon alfa
- Drug: isotretinoin
|
Interventional
|
Phase 2 |
- Hoag Memorial Hospital Presbyterian
- Cancer Biotherapy Research Group
|
Other |
- Primary Purpose: Treatment
|
|
|
All |
18 Years and older (Adult, Older Adult) |
NCT00002506 |
CDR0000077957
CBRG-9208
NBSG-9208
NCI-V92-0159 |
|
August 1992 |
January 1996 |
February 1999 |
July 26, 2004 |
May 12, 2011 |
|
- Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States - Bloomington Hospital
Bloomington, Indiana, United States - St. Vincent Hospital and Health Care Center
Indianapolis, Indiana, United States - (and 3 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: